21.27
0.89%
-0.19
Dopo l'orario di chiusura:
21.68
0.41
+1.93%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CPRX Giù?
Forum
Previsione
Catalyst Pharmaceuticals Inc Borsa (CPRX) Ultime notizie
Barclays PLC Boosts Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Wellington Management Group LLP Makes New $1.19 Million Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
We Ran A Stock Scan For Earnings Growth And Catalyst Pharmaceuticals (NASDAQ:CPRX) Passed With Ease - Simply Wall St
Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock - Yahoo Finance
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Sees Significant Increase in Short Interest - MarketBeat
Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Catalyst Pharmaceuticals to Present at JPMorgan's Prestigious Healthcare Conference 2025 - StockTitan
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by State Street Corp - MarketBeat
Jane Street Group LLC Raises Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Janus Henderson Group PLC - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals: Agamree Is Its Key To A Sustainable Future - Seeking Alpha
Verition Fund Management LLC Buys 43,447 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Bought by BNP Paribas Financial Markets - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Purchased by Charles Schwab Investment Management Inc. - MarketBeat
Jacobs Levy Equity Management Inc. Cuts Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch
Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock's On An Uptrend: Are Strong Financials Guiding The Market? - Yahoo Finance
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Short Interest Down 5.5% in November - MarketBeat
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term - Yahoo Finance
Martingale Asset Management L P Buys New Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Walleye Capital LLC Invests $4.94 Million in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Zacks Research Has Negative Estimate for CPRX Q4 Earnings - MarketBeat
Insiders At Catalyst Pharmaceuticals Sold US$4.4m In Stock, Alluding To Potential Weakness - Simply Wall St
Intech Investment Management LLC Purchases New Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Gary Ingenito Sells 12,000 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock - MarketBeat
Insider Selling: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Director Sells 17,500 Shares of Stock - MarketBeat
Catalyst Pharmaceuticals executive sells shares worth $272,654 By Investing.com - Investing.com Canada
Catalyst Pharmaceuticals director Harper sells $385,000 in stock By Investing.com - Investing.com Nigeria
Catalyst Pharmaceuticals director Harper sells $385,000 in stock - Investing.com
Catalyst Pharmaceuticals chief compliance officer sells $286,703 in stock - Investing.com
Catalyst Pharmaceuticals chief compliance officer sells $286,703 in stock By Investing.com - Investing.com UK
Capstone Investment Advisors LLC Makes New $708,000 Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
FORA Capital LLC Takes Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock - Yahoo Finance
Catalyst Pharmaceuticals Recognized as One of North - GlobeNewswire
Segall Bryant & Hamill LLC Makes New Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List - Yahoo Finance
Catalyst Pharmaceuticals chief medical officer sells $805,562 in stock - Investing.com India
Catalyst Pharmaceuticals chief medical officer sells $805,562 in stock By Investing.com - Investing.com South Africa
Catalyst Pharmaceuticals chairman sells $3.6 million in stock By Investing.com - Investing.com South Africa
Catalyst Pharmaceuticals Insider Trades Send A Signal - Benzinga
Pacer Advisors Inc. Cuts Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):